Seer, Inc. reported second quarter 2026 financial results with revenue of $3.1 million, a 23% decrease from the prior year period, driven by macroeconomic headwinds and elongated sales cycles. The company posted a net loss of $16.9 million compared to $19.4 million in the previous year, while maintaining full-year 2026 revenue guidance between $16 million and $18 million. Seer ended the quarter with approximately $209.5 million in cash, cash equivalents, and investments, and repurchased roughly 200,000 Class A common shares under its existing buyback program. Additionally, the company initiated an International Trade Commission investigation against Nanomics Biotechnology for alleged patent infringement and secured a favorable European Patent Office ruling regarding its licensed technology. Seer operates in the biotechnology industry, providing deep proteomic insights through its proprietary Proteograph product suite.
